Prognosis and Prognostic Factors of Serous Borderline Tumor-Micropapillary Variant: Retrospective Study of 200 Patients with Long-Term Follow-Up

Table 2

Prognostic factors for recurrence in women with SBOT-Ms ().

Variables		Disease-free survival (DFS)
		Univariate analysis			Multivariate analysis
		N recur/total (%)	5-year DFS (%)		Hazard ratio (95% CI)
Age (years)	> 35	10/75 (13.3)	86	<.001	1	.018
	≤ 35	71/125 (56.8)	39		2.4 (1.2-4.9)
Nulliparous	No	21/92 (22.8)	76	<.001	1	.152
	Yes	60/108 (55.6)	40		—
Surgical approach	Laparotomy	49/134 (36.6)	62	.066
	Laparoscopy	32/66 (48.5)	43
Staging surgery	Yes	42/127 (33.1)	64	.015	1	.054
	No	39/73 (53.4)	44		—
Lymphadenectomy	Yes	11/60 (18.3)	80	<.001	1	.281
	No	70/140 (50.0)	45		—
Surgical extent	Radical	8/78 (10.3)	89	<.001	1	<.001
	Conservative	73/122 (59.8)	36		5.8 (2.6-12.8)
Ovarian involvement	Unilateral	21/63 (33.3)	62	.128
	Bilateral	60/137 (43.8)	54
FIGO stage^†	I	45/106 (42.5)	56	.904
	II-IV	36/94 (38.3)	57
Stromal microinvasion	No	71/164 (43.3)	54	.114
	Yes	10/36 (27.8)	65
Type of implants ()	Noninvasive	25/68 (36.8)	58	.566
	Invasive	11/26 (42.3)	52
Chemotherapy	No	58/146 (39.7)	57	.887
	Yes	23/54 (42.6)	54

^†FIGO, International Federation of Gynecology and Obstetrics.